In this article
/ Download pdf version of this article
What are the changes?
- Azithromycin granules for oral liquid (40 mg/mL and 200 mg/5mL are now fully subsidised, with no requirement for endorsement
of the prescription (from 1 November, 2012).
- As of 1 December, 2012, a 250 mg azithromycin tablet will be available, fully subsidised, in addition to the current
500 mg tablet. This is because the 500 mg tablet is unscored and doses may be inaccurate if the tablets are broken.
- A restriction on the length of time azithromycin is able to be prescribed will now apply for all formulations. Azithromycin
will be able to be prescribed for a maximum of five days and for longer periods only if specific endorsement criteria apply
Some restrictions on funding are still in place
The following funding restriction will apply to all community dispensings of azithromycin 250 and 500 mg tablets:
- A maximum of five days treatment per prescription; which can be waived by endorsement for patients who have:
- Received a lung transplant and require treatment or prophylaxis for bronchiolitis obliterans syndrome (Currently
unapproved indication); or
- Cystic fibrosis and chronic infection with Pseudomonas aeruginosa or Pseudomonas-related gram-negative organisms (Currently
- A maximum of eight 500 mg tablets will continue to be available on PSO
The recommended indications for azithromycin remain the same
Recommended first-line indications for azithromycin are:
Chlamydia infections - Adults: 1 g stat
Infants born to mothers who have chlamydia are at increased risk of pneumonia and conjunctivitis. Treatment with azithromycin
suspension is appropriate if the infant has laboratory proven neonatal chlamydia conjunctivitis or pneumonia. The dose should
be discussed with a paediatrician.
Acute non-specific urethritis - Adults: 1 g stat
Pertussis (treatment and prophylaxis) - Children: 10 mg/kg on day one, followed by 5mg/kg/day for days
two to five (five days total treatment). For children weighing >45 kg, dose as per adults. Erythromycin is an alternative
to azithromycin in children aged over one year.
Erythromycin is also the current recommended treatment and prophylaxis for pertussis in adults. Azithromycin is an alternative:
500 mg on day one, followed by 250 mg on days two to five.
N.B. Previous guidance has given a different dosing regimen for azithromycin in children for pertussis, depending on age
(under or over age six months). United States, United Kingdom and Australian guidelines differ in their advice. The consensus
in New Zealand is now to use the same regimen in children, regardless of age.
Recommended second-line indications for azithromycin include:
- Pelvic inflammatory disease, as an alternative to doxycycline, when chlamydia is present - 1 g stat, repeated in seven
days + ceftriaxone 500 mg IM stat + metronidazole 400 mg, twice daily, for two weeks
Ensuring appropriate use of azithromycin
PHARMAC's proposal to remove the prescribing restrictions on azithromycin was initially outlined in July 2012. Feedback
on this proposal, however, raised concerns that the removal of all restrictions would result in inappropriate prescribing
of azithromycin. In particular, there were concerns that the medicine would be used for its anti-inflammatory properties,
that it would be used for the treatment of conditions for which other antibiotics are effective and more appropriate, or
as a long-term prophylactic in chronic obstructive pulmonary disease (COPD). It was thought that the widened access to azithromycin
would increase the prevalence of azithromycin-resistant micro-organisms in New Zealand. There were also questions raised
about the safety of the use of azithromycin due to recent evidence linking azithromycin with an increase in cardiovascular
In response to this feedback, PHARMAC altered the proposal allowing azithromycin to be funded without restriction and
re-issued it with the restrictions as outlined.
Prescribing notes for azithromycin
Appropriateness of the indication
The recommended indications for the use of azithromycin remain the same. Azithromycin is not recommended for use in the
majority of patients with upper or lower respiratory tract infections such as otitis media, sore throat or community -acquired
Anti-inflammatory properties in long-term conditions
Macrolide antibiotics, such as azithromycin, have immunomodulatory and anti-inflammatory effects in addition to their
antimicrobial activity and in patients with some conditions, e.g. cystic fibrosis, this can be beneficial. Azithromycin
has been subsidised since 1 July, 2009 for use in patients with cystic fibrosis and chronic infection. There may be a role
for azithromycin in patients with non-cystic fibrosis bronchiectasis. The evidence for this is currently under review and
the indication will be widened if appropriate.
Long-term prophylaxis in patients with COPD
There is increasing evidence that the long-term use of azithromycin may decrease the frequency of exacerbations in people
with COPD and improve their quality of life. However, concerns about adverse effects and antibiotic resistance, mean that
routine use is not recommended. In a recent study of the use of azithromycin in people with COPD, approximately 5% of participants
experienced a reduction in hearing after use of azithromycin, which was not always reversed on cessation.2 Significant
concerns were also raised regarding resistance to macrolides. The authors acknowledge that there was an increase in the
incidence of colonisation with macrolide-resistant organisms but that the significance of this for the patient, their families
and the community is unknown.2
Widened access and increasing use of azithromycin in other countries have contributed to an increasing incidence of macrolide-resistant
organisms.3 Concerns have been raised that a similar situation will arise in New Zealand. It is therefore important
that azithromycin is only prescribed for the clinical situations it is indicated for. ESR will be monitoring resistance
data in New Zealand.
Azithromycin may be linked to an increased risk of cardiovascular death
A large retrospective cohort study found that a five day course of azithromycin was associated with a small increase
in the risk of cardiovascular death when compared to the risk in patients who took no antibiotics or other antibiotics,
e.g. amoxicillin.1 Macrolide antibiotics, particularly erythromycin and clarithromycin have been associated
with prolongation of the QT interval and there is increasing evidence that azithromycin may also be proarrhythmic.4 Although
there has been criticism of the study and further research is required, the authors conclude that the key factors that
need to be considered when prescribing azithromycin are the patient's baseline cardiovascular risk and the appropriateness
of the indication for which azithromycin is prescribed.1,4
ACKNOWLEDGEMENT: Thank you to Dr Emma Best, Paediatric Infectious
Diseases Consultant, Starship Children's Health, Auckland and Dr Simon Briggs, Clinical Director, Infectious
Diseases Service, Auckland City Hospital, Auckland for expert guidance in developing this article.
- Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. NEJM 2012;366(20):1881-90.
- Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. NEJM 2011;365(8):689-98.
- Jenkins S, Farrell D. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009;15.